{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:39:22Z","timestamp":1761745162136,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128203231"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004432","name":"College of Dentistry, King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004432","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016148","name":"Department of Pharmaceutical Chemistry, University of Kansas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016148","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.podrm.2019.10.001","type":"book-chapter","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T08:54:17Z","timestamp":1575622457000},"page":"1-39","source":"Crossref","is-referenced-by-count":5,"title":["Azilsartan medoxomil"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2019.10.001_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/B:CEPR.0000012389.01561.27","article-title":"Beta-blocker efficacy according to heart rate and rhythm in patients with heart failure. Commentary on the Cardiac Insufficiency Bisoprolol Study II analysis","volume":"7","author":"Lechat","year":"2003","journal-title":"Card. Electrophysiol. Rev."},{"key":"10.1016\/bs.podrm.2019.10.001_bib2","unstructured":"Index Nominum: International Drug Directory, E.b.t.S.P.S.m.S.P., Stuttgart, Germany. Available from: Micromedex\u00ae 2.0, (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http:\/\/www.micromedexsolutions.com\/."},{"key":"10.1016\/bs.podrm.2019.10.001_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.fjc.0000184117.76188.68","article-title":"Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol","volume":"46","author":"Nozawa","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/bs.podrm.2019.10.001_bib4","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/bs.podrm.2019.10.001_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1248\/bpb.28.876","article-title":"Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients","volume":"28","author":"Taguchi","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/bs.podrm.2019.10.001_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.amjcard.2003.07.009","article-title":"Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation","volume":"92","author":"Katritsis","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.podrm.2019.10.001_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2710.2003.00477.x","article-title":"A comparison of the beta1-selectivity of three beta1-selective beta-blockers","volume":"28","author":"Nuttall","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/bs.podrm.2019.10.001_bib10","first-page":"873","article-title":"Use of bisoprolol in heart failure. The BISOCOR observational study","volume":"56","author":"Gonzalez-Juanatey","year":"2003","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/bs.podrm.2019.10.001_bib12","unstructured":"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Azilsartan#section=2D-Structure, 25\/03\/2019."},{"key":"10.1016\/bs.podrm.2019.10.001_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00392-003-0959-7","article-title":"Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II))","volume":"92","author":"Bohm","year":"2003","journal-title":"Z. Kardiol."},{"key":"10.1016\/bs.podrm.2019.10.001_bib14","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2165\/00003495-200262180-00017","article-title":"Bisoprolol: a review of its use in chronic heart failure","volume":"62","author":"McGavin","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/bs.podrm.2019.10.001_bib15","series-title":"The Merck Index - an Encyclopedia of Chemicals, Drugs, and Biologicals","first-page":"161","author":"O'Neil","year":"2013"},{"issue":"11","key":"10.1016\/bs.podrm.2019.10.001_bib16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.clinthera.2011.10.007","article-title":"Azilsartan medoxomil: a new angiotensin receptor blocker","volume":"33","author":"Zaiken","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/bs.podrm.2019.10.001_bib17","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/200796s006lbl.pdf. Edarbi (azilsartan medoxomil) tablets (2014) U.S. prescribing information. Arbor Pharmaceuticals. Accessed 22 August 2015."},{"issue":"15","key":"10.1016\/bs.podrm.2019.10.001_bib18","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1021\/jm00067a016","article-title":"Nonpeptide angiotensin I1 receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids","volume":"36","author":"Keiji Kubo","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.podrm.2019.10.001_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1515\/cipms-2015-0047","article-title":"An alternative synthesis of azilsartan: an angiotensin II receptor blocker","author":"Garaga","year":"2015","journal-title":"Curr. Issues Pharm. Med. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.001_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1021\/op3002867","article-title":"Improved process for azilsartan medoxomil: a new angiotensin receptor blocker","volume":"17","author":"R\u00e1dl","year":"2013","journal-title":"Org. Process Res. Dev."},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.001_bib21","first-page":"514","article-title":"Commercial synthesis of azilsartan kamedoxomil: an angiotensin II receptor blocker organic process","volume":"19","author":"Garaga","year":"2015","journal-title":"Res. Dev."},{"key":"10.1016\/bs.podrm.2019.10.001_bib22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/heart.88.6.611","article-title":"Beta blockers in older persons with heart failure: tolerability and impact on quality of life","volume":"88","author":"Baxter","year":"2002","journal-title":"Heart"},{"year":"2014","series-title":"Crystalline Forms of Azilsartan and Preparation and Uses Thereof, in Patent Application Publication","author":"Lei","key":"10.1016\/bs.podrm.2019.10.001_bib23"},{"year":"2016","series-title":"Crystalline Forms of Azilsartan Medoxomil Potassium and Preparation and Uses Thereof","author":"Lei","key":"10.1016\/bs.podrm.2019.10.001_bib24"},{"issue":"5","key":"10.1016\/bs.podrm.2019.10.001_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.5958\/0974-4150.2018.00139.6","article-title":"UV spectrophotometric method for the estimation of azilsartan medoxomil in bulk form","volume":"11","author":"Gawai","year":"2018","journal-title":"Asian J. Res. Chem."},{"issue":"8","key":"10.1016\/bs.podrm.2019.10.001_bib26","first-page":"670","article-title":"Development and validation of spectrophotometric methods for simultaneous estimation of azilsartan kamedoxomil and amlodipine besylate in synthetic mixture","volume":"7","author":"Rathod Nidhi","year":"2018","journal-title":"World J. Pharm. Res."},{"issue":"8","key":"10.1016\/bs.podrm.2019.10.001_bib27","first-page":"948","article-title":"Development and validation of spectrophotometric method for simultaneous estimation of azilsartan kamedoxomil and cilnidipine in synthetic mixture","volume":"7","author":"Jani","year":"2018","journal-title":"World J. Pharm. Res."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.001_bib28","first-page":"1667","article-title":"UV spectrophotometric method for the estimation of Azilsartan medoxomil in bulk and pharmaceutical formulations","volume":"4","author":"Surwade","year":"2015","journal-title":"World J. Pharm. Res."},{"issue":"6","key":"10.1016\/bs.podrm.2019.10.001_bib29","first-page":"840","article-title":"UV-spectrophotometric method development and validation of azilsartan medoxomil in pharmaceutical dosage form","volume":"3","author":"Aher","year":"2014","journal-title":"World J. Pharm. Res."},{"key":"10.1016\/bs.podrm.2019.10.001_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/ACI.S13768","article-title":"Spectrophotometric and spectrofluorimetric studies on azilsartan medoxomil and chlorthalidone to be utilized in their determination in pharmaceuticals","volume":"9","author":"Ebeid","year":"2014","journal-title":"Anal. Chem. Insights"},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.001_bib31","first-page":"7","article-title":"A validated spectrophotometric method for determination of azilsartan medoxomil in pharmaceutical dosage form","volume":"2","author":"Pradeepthi","year":"2013","journal-title":"J. Sci. Res. Pharm."},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.001_bib32","first-page":"1133","article-title":"New simple UV spectrophotometric method for determination of azilsartan medoxomil in bulk and pharmaceutical dosage forms","volume":"4","author":"Gorla","year":"2013","journal-title":"Int. J. Res. Pharmaceut. Biomed. Sci."},{"issue":"5","key":"10.1016\/bs.podrm.2019.10.001_bib33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.4314\/tjpr.v15i5.15","article-title":"A novel method to determine new potent angiotensin inhibitor, azilsartan, in human plasma via micelle-enhanced spectrofluorimetry using cremophor RH 40","volume":"15","author":"Darwish","year":"2016","journal-title":"Trop. J. Pharm. Res."},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.001_bib34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3724\/SP.J.1123.2010.00253","article-title":"Analysis of diuretics by capillary electrochromatography using poly(1-hexadecene-co-TMPTMA) monolithic column","volume":"28","author":"Lu","year":"2010","journal-title":"Chin. J. Chromatogr."},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.001_bib35","first-page":"146","article-title":"Development and validation of HPTLC method for estimation of azilsartan medoxomil in bulk and pharmaceutical dosage forms","volume":"2","author":"Gorla","year":"2015","journal-title":"Int. J. Pharm. Pharm. Res."},{"issue":"1","key":"10.1016\/bs.podrm.2019.10.001_bib36","first-page":"224","article-title":"Development and validation of stability indicating HPTLC method for estimation of azilsartan medoximil","volume":"6","author":"Gandhi","year":"2015","journal-title":"Pharma Sci. Monit."},{"issue":"2","key":"10.1016\/bs.podrm.2019.10.001_bib37","first-page":"164","article-title":"5. Development and validation of a bioanalytical RP-HPLC method for azilsartan medoxomil with liquid-liquid extraction","volume":"8","author":"Karpe","year":"2016","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2019.10.001_bib38","first-page":"22","article-title":"Development and validation of analytical method for simultaneous estimation of Azilsartan medoxomil and Amlodipine besylate in synthetic mixture","volume":"2","author":"Zankat","year":"2015","journal-title":"Pharm. Chem. J."},{"issue":"10","key":"10.1016\/bs.podrm.2019.10.001_bib39","first-page":"1887","article-title":"HPLC determination of azilsartan tablets dissolution","volume":"19","author":"Li","year":"2015","journal-title":"Anhui Yiyao"},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.001_bib40","first-page":"316","article-title":"A novel stability indicating validated RP-HPLC method for simultaneous determination of azilsartan and amlodipine besylate hydrochloride in bulk and tablet dosage form","volume":"2","author":"Swamy","year":"2015","journal-title":"Eur. J. Biomed. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2019.10.001_bib41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jchromb.2015.07.047","article-title":"Development, validation and application of the liquid chromatography tandem mass spectrometry method for simultaneous quantification of azilsartan medoxomil (TAK-491), azilsartan (TAK-536), and its 2 metabolites in human plasma","volume":"1001","author":"Kuze","year":"2015","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"issue":"41","key":"10.1016\/bs.podrm.2019.10.001_bib42","first-page":"3907","article-title":"Content determination of azilsartan tablets by HPLC","volume":"25","author":"Zhang","year":"2014","journal-title":"Zhongguo Yaofang"},{"key":"10.1016\/bs.podrm.2019.10.001_bib43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jchromb.2015.03.018","article-title":"Simultaneous determination of azilsartan and chlorthalidone in rat and human plasma by liquid chromatography-electrospray tandem mass spectrometry","volume":"990","author":"Ramakrishna","year":"2015","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"issue":"6","key":"10.1016\/bs.podrm.2019.10.001_bib44","first-page":"236","article-title":"Stability-indicating RP-HPLC method for the simultaneous estimation of Azilsartan medoxomil and chlorthalidone in solid dosage forms","volume":"6","author":"Naazneen","year":"2014","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2019.10.001_bib45","first-page":"572170","article-title":"Development and validation of RP-HPLC method for Azilsartan Medoxomil Potassium quantitation in human plasma by solid phase extraction procedure","author":"Vekariya","year":"2013","journal-title":"ISRN Spectrosc."},{"key":"10.1016\/bs.podrm.2019.10.001_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/572170","article-title":"Development and validation of RP-HPLC method for azilsartan medoxomil potassium quantitation in human plasma by solid phase extraction procedure","volume":"2013","author":"Vekariya","year":"2013","journal-title":"ISRN Spectrosc."},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.001_bib47","first-page":"247","article-title":"UPLC\u2013MS\/MS for the determination of azilsartan in beagle dog plasma and its application in a pharmacokinetics study","volume":"10","author":"Gong","year":"2015","journal-title":"Asian J. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.001_bib48","doi-asserted-by":"crossref","first-page":"708","DOI":"10.5958\/0974-360X.2017.00133.0","article-title":"Analytical and bioanalytical method for quantification of pure azilsartan, not its salts by RP-HPLC","volume":"10","author":"Naykode","year":"2017","journal-title":"Res. J. Pharm. Technol."},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.001_bib49","first-page":"737","article-title":"Determination of azilsartan in healthy human plasma by liquid chromatography-tandem mass spectrometry and its preliminary study on pharmacokinetics","volume":"37","author":"CAO","year":"2017","journal-title":"Chin. J. Pharmaceut. Anal."},{"issue":"4","key":"10.1016\/bs.podrm.2019.10.001_bib50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10337-017-3276-4","article-title":"Development using response surface methodology and validation of a stability-indicating RP-HPLC method for simultaneous estimation of azilsartan medoxomil and chlorthalidone in solid dosage form","volume":"80","author":"Ruhul Kayesh","year":"2017","journal-title":"Chromatographia"},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.001_bib51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/chromsci\/bmy102","article-title":"Stability-indicating RP-UPLC method for simultaneous determination of azilsartan medoxomil and chlorthalidone in tablets in the presence of its degradation products","volume":"57","author":"Hussein","year":"2018","journal-title":"J. Chromatogr. Sci."},{"issue":"5","key":"10.1016\/bs.podrm.2019.10.001_bib52","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5246\/jcps.2014.05.041","article-title":"Characterization of two degradation products of azilsartan formed during the micronization process and development of a method to control the degradation","volume":"23","author":"Sui","year":"2014","journal-title":"J. Chin. Pharm. Sci."},{"issue":"19","key":"10.1016\/bs.podrm.2019.10.001_bib53","first-page":"105","article-title":"Identification of the degradation compounds of azilsartan by LC-MS","volume":"42","author":"Wu","year":"2014","journal-title":"Guangzhou Huagong"},{"issue":"15","key":"10.1016\/bs.podrm.2019.10.001_bib54","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/rcm.7235","article-title":"Liquid chromatography\/tandem mass spectrometry study of forced degradation of azilsartan medoxomil potassium","volume":"29","author":"Swain","year":"2015","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/bs.podrm.2019.10.001_bib55","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jpba.2015.12.027","article-title":"Forced degradation, LC\u2013UV, MSn and LC\u2013MS\u2013TOF studies on azilsartan: identification of a known and three new degradation impurities","volume":"120","author":"Kaushik","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"26","key":"10.1016\/bs.podrm.2019.10.001_bib56","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.1007\/s00216-014-8085-0","article-title":"Stability-indicating RP-LC method for determination of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms: application to degradation kinetics","volume":"406","author":"Ebeid","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"issue":"12","key":"10.1016\/bs.podrm.2019.10.001_bib57","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1Q468","article-title":"Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension","volume":"45","author":"Baker","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/bs.podrm.2019.10.001_bib58","first-page":"200","article-title":"Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol","volume":"36","author":"Harting","year":"1986","journal-title":"Arzneimittelforschung"},{"issue":"10","key":"10.1016\/bs.podrm.2019.10.001_bib59","first-page":"634","article-title":"Azilsartan medoxomil (Edarbi): the eighth angiotensin II receptor blocker","volume":"36","author":"Jones","year":"2011","journal-title":"Pharm. Therapeut."},{"issue":"3","key":"10.1016\/bs.podrm.2019.10.001_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425255.2013.769521","article-title":"Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension","volume":"9","author":"Angeli","year":"2013","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/bs.podrm.2019.10.001_bib61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1472-8206.2006.00408.x","article-title":"Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein","volume":"20","author":"Bachmakov","year":"2006","journal-title":"Fundam. Clin. Pharmacol."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology","Profiles of Drug Substances, Excipients, and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512519300160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512519300160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:34:21Z","timestamp":1761730461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512519300160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128203231"],"references-count":58,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2019.10.001","relation":{},"ISSN":["1871-5125"],"issn-type":[{"type":"print","value":"1871-5125"}],"subject":[],"published":{"date-parts":[[2020]]}}}